FLI1 and neoplasm: The first strategy involves binding to receptors expressed specifically on the target cells; for example, antibody‒drug conjugates (ADCs) may improve the targeting of topoisomerase inhibitors (a kind of FLI-1 inhibitors) to tumour cells for increased effectiveness.